LLY News and Press, Eli Lilly and Company From 03/14/24

2024-03-14 15:45:17 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...

2024-03-14 11:44:36 ET More on Eli Lilly Eli Lilly and Co (LLY) Cowen's 44th Annual Health Care Conference (Transcript) Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly in pact with ...

2024-03-14 08:30:00 ET Over the past year, Eli Lilly (NYSE: LLY) has impressed investors on almost every front. Financial results have been excellent, clinical progress has been solid, and its stock has crushed the broader market. If there is one area where Eli Lilly hasn't been...

2024-03-14 07:20:30 ET More on WuXi AppTec, WuXi AppTec, etc. Potential U.S. Targeting Casts Shadow Over WuXi AppTec Family WuXi Biologics: Recent Share Price Recovery Isn't Sustainable Historical earnings data for WuXi AppTec Dividend scorecard for WuXi AppT...

2024-03-13 13:29:04 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...

2024-03-13 09:45:00 ET It's difficult to find a group of companies that have performed better than the "Magnificent Seven" in the past decade. This clique includes the following market leaders: Alphabet , Amazon , Apple , Meta Platforms , Microsoft , Nvidia , and T...

2024-03-13 07:47:31 ET More on Eli Lilly Eli Lilly and Co (LLY) Cowen's 44th Annual Health Care Conference (Transcript) Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly eczema drug s...

2024-03-13 05:03:00 ET Viking Therapeutics (NASDAQ: VKTX) shares soared more than 120% in one trading session last month as investors bet on its ability to win in the billion-dollar weight-loss drug market -- or attract a buyer. The biotech company announced positive clinical trial ...

2024-03-12 13:11:55 ET More on AnaptysBio Stifel starts AnaptysBio at buy, cites upcoming catalysts AnaptysBio gains as Piper Sandler starts at Overweight on catalyst path Seeking Alpha’s Quant Rating on AnaptysBio Historical earnings data for AnaptysB...

2024-03-12 12:28:18 ET Summary iShares Core S&P U.S. Growth ETF implements a systematic strategy based on six valuation and growth metrics. Like most large-cap growth funds, the IUSG ETF is overweight in technology and in its top holdings. Quality metrics are attractive, y...